Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 12/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507719 | 0.87 | PRMT6 (0.41) | RXFP1LMNANPSR1 | |
| SCHEMBL2404929 | 0.85 | RXFP1 (0.44) | RXFP1STING1LMNARAPGEF3GMNN | |
| SCHEMBL5505121 | 0.83 | RXFP1 (0.43) | RXFP1STING1LMNARAPGEF3GMNN | |
| SCHEMBL16242977 | 0.83 | RXFP1 (0.42) | RXFP1STING1LMNARAPGEF3GMNN | |
| SCHEMBL26882824 | 0.82 | STING1 (0.45) | RXFP1STING1LMNARAPGEF3GMNN | |
| SCHEMBL2522409 | 0.82 | ADORA3 (0.44) | RXFP1STING1LMNARAPGEF3GMNN | |
| SCHEMBL12212793 | 0.82 | ADORA3 (0.44) | RXFP1STING1LMNARAPGEF3GMNN | |
| SCHEMBL16243333 | 0.81 | RXFP1 (0.41) | RXFP1STING1LMNARAPGEF3GMNN | |
| SCHEMBL16271116 | 0.80 | KMT2A (0.41) | RXFP1STING1LMNARAPGEF3GMNN | |
| SCHEMBL12352443 | 0.80 | KMT2A (0.41) | RXFP1STING1LMNARAPGEF3GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-10478449-B2 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180200282-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180104271-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180104272-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9943539-B1 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943538-B1 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180028555-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9827263-B2 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150366894-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | ISIS PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20040147022-A1 | 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations | ISIS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004043977-A2 | 2’-FLUORO SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004044140-A2 | 2’-SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | ISIS PHARMACETICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-6639062-B2 | Oligonucleotides which elicit ribonuclease for cleavage in complementary nucleic acid strand, having increased binding affinity/nuclease resistance; for medical diagnosis, gene therapy | ISIS PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| US-20030181693-A1 | Oligonucleotide analogs having modified dimers | COOK PHILLIP DAN (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030088079-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6420549-B1 | NUCLEOTIDE SEQUENCES FOR USE AS TOOLS IN GENETIC ENGINEERING AND CONTROLLING TRANSLATION | ISIS PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| US-6194598-B1 | Aminooxy-modified oligonucleotide synthetic intermediates | ISIS PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | disclosed |
| US-6172209-B1 | MOLECULAR HYBRIDIZATION, GENETIC ENGINEERING; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | disclosed |
| US-6127533-A | SPECIFICALLY HYBRIDIZABLE WITH A SELECTED SEQUENCE OF RNA OR DNA; DIAGNOSIS OF DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | RXFP1 4274/4885STING1 1748/4885LMNA 953/4885 |
| US-20180200282-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | RXFP1 4274/4885STING1 1748/4885LMNA 953/4885 |
| US-10478449-B2 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | NSUN2, SNRPE, RBM3 | RXFP1 4296/4885STING1 1730/4885LMNA 913/4885 |
| US-20150366894-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | RXFP1 4274/4885STING1 1748/4885LMNA 953/4885 |
| US-20030181693-A1 | Oligonucleotide analogs having modified dimers | RNASEL, ADAR, RNGTT | RXFP1 4378/4885STING1 3305/4885LMNA 1778/4885 |
| US-20180028555-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | RXFP1 4274/4885STING1 1748/4885LMNA 953/4885 |
| US-20030088079-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | HNRNPM, RNASEH1, HNRNPF | RXFP1 3804/4885STING1 2478/4885LMNA 680/4885 |
| US-20180104272-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | RXFP1 4274/4885STING1 1748/4885LMNA 953/4885 |
| US-20180104271-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | RXFP1 4274/4885STING1 1748/4885LMNA 953/4885 |
| US-20040147022-A1 | 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations | NSUN2, SNRPE, HNRNPC | RXFP1 4181/4885STING1 1792/4885LMNA 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.